Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent ...
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...